Novartis AG has agreed to acquire Medicines Co. for a $6.8 billion deal. This opens the door to discovering a promising cure for high cholesterol. This is another purchase for Novartis.
The Swiss-based pharmaceutical giant, in addition to expanding its portfolio and taking on the development of the cholesterol drug, will also implement a remedy for various heart defects. In this way, Novartis reaffirms its leading position as a pharmaceutical company focused on the latest cancer drugs, rare diseases and other diseases.
Novartis is already developing products like Zolgensma. This medicine is based on gene therapy that fights diseases that destroy muscle tissue. The development came after the Swiss company bought AveXis in 2018 for $ 8.7 billion. Last year, Endocyte was also purchased for $2.1 billion.
Source: Bloomberg Finance L.P.
Read more:
25 Canada Square, Level 33, office 50, Canary Wharf London, E14 5LQ +44 20 3608 6256
World Financial Markets - 0700 17 600 Varchev Exchange - 0700 115 44
Varchev Finance Ltd is registered in the FCA (FINANCIAL CONDUCT AUTHORITY) with a passport in the United Kingdom: FCA, United Kingdom - registration number: 494 045, which allows provision of financial services in the United Kingdom.
Varchev Finance Ltd strictly comply with the statutes of the European directive MiFID (Markets in Financial Instruments). targeting increased efficiency, transparency and uniformity of financial instruments.
Varchev Finance Ltd is authorized and regulated by the Financial Supervision Commission - Sofia, Bulgaria: License number RG-03-02-05 / 15.03.2006
The information on this site is not intended for distribution or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
Disclaimer:
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 63,41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.